Banyu Pharmaceutical Co. Ltd

Msd K.k.

Vertex Pharmaceuticals, Inc.

Other

Mitsubishi Denki Kabushiki Kaisha

Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Taiho Pharmaceutical Company Limited

Mitsuru Ohkubo

Nobuhiko Kawanishi

Hiroyuki Suda

Katsuhisa Kojiri

Hisao Kondo

Hiroharu Arakawa

Takashi Mita

Tetsuya Kato

Michael P Mortimore

Yoshikazu Iwasawa

Kenji Niiyama

Katsumasa Nonoshita

Tomoko Sunami

Toshiyasu Shimomura

Lihu Yang

Hayley Marie Binch

Jun Shibata

Toshio Kamei

Takashi Nomoto

Tomoharu Iino

Yoshimi Tsuchiya

Masahiro Hayashi

Toshihiko Satoh

Takeru Yamakawa

Yasufumi Nagata

Masayuki Nakamura

Hideki Jona

Masaya Hashimoto

Jun Kusunoki

Hideaki Imamura

Koji Yamada

Hitoshi Masaki

Yumiko Sakuma

Toshiharu Iwama

Christopher I Bayly

Hideki Kurihara

Keita Nagai

Kaori Kamijo

Kouta Masutani

Naohiro Tsukamoto

Michael Mortimore

The present invention provides an imidazooxazine compound represented by Formula (I) or a salt thereof, wherein A, B, C, and D are as defined in the specification.

Imidazo-oxazine compound or salt thereof

The present invention relates to a compound of formula I: wherein: Ris a hydrogen atom, F, CN, etc.; Ris CO, SO, etc.; Ris a phenyl which may be substituted; X, X, and Xeach independently CH, N, etc. provided, however, that among X, Xand X, the number of nitrogen is 0 or 1; W is the following residue: wherein: W, W, and Weach independently CH, N, etc., or a pharmaceutically acceptable salt or ester thereof. 

Aminopyridine derivatives having aurora a selective inhibitory action

The present invention relates to a compound of Formula (I): wherein Ris H or Calkyl; Ris H or Calkyl; Rand Rare each independently H or Calkyl, where the alkyl may be substituted with one to three of the same or different substituents selected from R; Ris H, hydroxy, Calkyl, or OCH; and Ris F or Cl, or a pharmaceutically acceptable salt or ester thereof.

Aminopyridine derivatives having Aurora A selective inhibitory action

The present invention relates to a compound of Formula (I): wherein: Ris H, &#x2014;NHCOOR, Ccycloalkyl, or phenyl; where the cycloalkyl and phenyl each independently may be substituted with one to three of the same or different substituents selected from R; Ris Calkyl which may be substituted with one to three of the same or different substituents selected from F and Cl; Ris H, &#x2014;COOH, &#x2014;CHCOOH, &#x2014;COOR, or &#x2014;CHCOOR; Ris Calkyl, where the alkyl may be substituted with one to three of the same or different substituents selected from halogen atoms; Ris H, Calkyl, where the alkyl may be substituted with one to three of the same or different substituents selected from R; Ris F, Cl, CF, or Calkyl; Ris halogen atom, hydroxy, or cyano; W is selected from: Wis H, halogen atom, cyano, Calkyl, or Ccycloalkyl, or a pharmaceutically acceptable salt or ester thereof. 

The present invention relates to a compound of Formula (I): 

The present invention relates to a compound of general formula I: wherein:

The invention relates to a compound of a formula (I): or a pharmaceutically acceptable salt or ester thereof, useful as a therapeutic agent for various ACC-related disorders. 

Spirochromanone derivatives as acetyl coenzyme A carboxylase (ACC) inhibitors

The present invention relates to a compound of formula I:  

Aminopyridine derivatives having aurora A selective inhibitory action

The present invention relates to a compound represented by the general formula (I): wherein mand mare 1, 2, or 3; nand nare 0 or 1; i is an integer of any of 1 to m; j is an integer of 1 to m; R is aryl, heteroaryl, or cycloalkyl any of which may be substituted; Rand R' is hydrogen atom, etc. and Rand R&#x2032; is hydrogen atom, etc.; R, R, and Rare hydrogen atom, etc; Xis CH, CX, or N; Xis CH, N, etc.; Xis CH, N, etc.; Xis CH or N; Y, Y, and Yare each independently CH or N; Zand Zare each independently CH or N; W is a 5-membered aromatic heterocyclic group such as pyrazolyl, thiazolyl, etc., or a pharmaceutically acceptable salt or ester thereof; a pharmaceutical composition or antitumor agent containing the same; and combinations of the antitumor agent with other antitumor agent(s).

The invention relates to a compound of a formula (I): or a pharmaceutically acceptable salt or ester thereof, useful as a therapeutic agent for various ACC-related disorders.

Spirochromanone derivatives

The invention relates to isoxazolopyridone derivatives of a formula (I-a): wherein Rrepresents an optionally-substituted heteroaryl or phenyl group, Rrepresents an optionally-substituted phenyl or heteroaryl group, and Rrepresents a methyl group, provided that, (1) when Ris an unsubstituted phenyl group, then Rmust not be a para-substituted phenyl group of which the substituent is any of a methoxy group, a chloro group, a methyl group, a trifluoromethyl group, a fluoro group, a bromomethyl group or a dimethylaminomethyl group, and Rmust not be an unsubstituted heteroaryl group, and (2) when Ris a 4-tolyl group or a 4-fluorophenyl group, then Rmust not be an unsubstituted phenyl group, a 4-methoxyphenyl group or a 4-fluorophenyl group, or their pharmaceutically-acceptable salts. The isoxazolopyridone derivatives or their pharmaceutically-acceptable salts of the invention have a metabotropic glutamic acid receptor-antagonistic effect, and are useful for remedy of, for example, anxiety disorders, psychosomatic disorders, obsessive-compulsive neurosis, bipolar disorders, melancholia, eating disorders, schizophrenia, multi-infarct dementia, Alzheimer disease, epilepsy, Parkinson disease, Huntington's chorea, pain or retrograde neurosis.

Isoxazolopyridone derivatives and their use

Indolopyrrolocarbazole derivatives and antitumor agents

A diode-incorporated solar battery, which is intended to minimize an increase in production cost and a decrease in reliability that are involved in incorporating diodes into the solar battery, and to reduce the area of the surface electrodes of the solar battery so as to increase the electric power generation of the solar battery, wherein to this end, a connecting metal fixture for interconnecting solar cells has added thereto projection for parallel-connecting the solar cells and diodes.

Solar battery

Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors

Growing community of inventors

Ushiku, Japan

Mitsuru Ohkubo